Zentiva, the European generic business of Sanofi (http://www.sanofi.it/l/it/it/index.jsp), is at the center of exclusive negotiations between the French pharma company and global investor Advent International. The deals value is €1,9 billion, according to the companies. Advent will support the Zentiva management team to invest in the company’s operations, production facilities and R&D pipeline. The transaction is expected to close by the end of 2018.

LEAVE A REPLY

Please enter your comment!
Please enter your name here